July 25, 2026 · Gynecologic oncology reports · DOI: 10.1016/j.gore.2026.102171

Preclinical in vitro and in vivo activity of trastuzumab deruxtecan against <em>ERBB2</em>-mutated cervical carcinomas with low HER2 expression

Listen to this summary

The authors investigate the efficacy of trastuzumab deruxtecan (T-DXd) as a targeted therapy for cervical carcinomas with somatic HER2 mutations, specifically focusing on those with low HER2 expression. Their findings demonstrate that T-DXd significantly outperforms control treatments in both in vitro and in vivo models of HER2-S310F-mutated cervical cancer, suggesting it could be a promising therapeutic option for patients with recurrent cervical cancer harboring ERBB2 mutations.

Namrata Sethi, Sarah Ottum, Stefania Bellone, Cem Demirkiran, Natalia Buza, Pei Hui, Orazio De Tommasi, Luca Palmieri, Victoria M Ettorre, Michelle Greenman, Tobias M Hartwich, Elena Ratner, Alessandro D Santin

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play